Stock Market & Financial Investment News

News Breaks October 1, 2012 09:05 EDT AZN AstraZeneca suspends buyback program, confirms 2012 outlook AstraZeneca announced that it is suspending share repurchases with immediate effect. During 2012 the company has completed net share repurchases of $2.3B in respect of its initial target of $4.5B. AstraZeneca confirms its EPS target range for 2012 is maintained at $6.00 to $6.30. Pascal Soriot, Chief Executive Officer, AstraZeneca said: "As I assume my new responsibilities at AstraZeneca, I believe this is a prudent step that maintains flexibility while the Board and I complete the company's ongoing annual strategy update."    News For AZN From The Last 14 Days Check below for free stories on AZN the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 24, 2013 16:07 EDT AZN Actavis confirms appeal court issues injunction related to Resupules Actavis (ACT) confirmed that the United States Court of Appeals for the Federal Circuit has granted a motion by AstraZeneca (AZN) to enjoin Actavis from further distribution of its generic version of AstraZeneca's Pulmicort Respules 0.25, 0.5 mg products, pending resolution of AstraZeneca's appeal before the court. 08:22 EDT AZN Leerink's biotech analysts hold an analyst/industry conference call Subscribe for More Information May 22, 2013 09:01 EDT AZN Par Pharmaceutical begins shipment of generic Atacand Subscribe for More Information May 21, 2013 09:29 EDT AZN AstraZeneca says Phase III studies of Naloxegol met primary, secondary endpoints AstraZeneca (AZN) presented the results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies. Data was presented at the Digestive Disease Week meeting in Orlando, Florida. The primary endpoint in both trials was percentage of OIC responders, versus placebo, over 12 weeks of treatment. The secondary endpoints included the 12-week response rate in a laxative inadequate response population, the median time to first spontaneous bowel movement and the number of days per-week with at least one bowel movement. Plans for naloxegol will be finalized over the coming months, incorporating the outcome of ongoing discussions with health authorities in the US, EU and Canada, the company said. Naloxegol, a peripherally-acting mu-opioid receptor antagonist, has been specifically designed for the treatment of opioid-induced constipation and is part of the exclusive worldwide license agreement announced on 21 September 2009, between AstraZeneca and Nektar Therapeutics (NKTR). May 17, 2013 10:36 EDT AZN Leerink's major/specialty pharma analyst holds analyst/Industry conference call Subscribe for More Information 08:41 EDT AZN Impax commenced shipment of authorized generic Zomig Impax (IPXL) announced that its generics division, Global Pharmaceuticals, commenced shipment of authorized generic Zomig tablets, as part of an agreement with AstraZeneca (AZN). Zomig is indicated for the treatment of migraine headaches in adults. According to IMS Health data, U.S. sales of Zomig tablets and orally disintegrating tablets were approximately $196M in the 12 months ended April 2013. May 14, 2013 07:24 EDT AZN EBD Group to host a conference BioTrinity 2013 is being held in Newbury, England on May 14-16. May 13, 2013 16:53 EDT AZN Optimer gets bids from AstraZeneca, Cubist, Astellas, Bloomberg says Optimer (OPTR) has received first round bids from AstraZeneca (AZN), Cubist (CBST), and Astellas, reports Bloomberg, citing people familiar with the matter. Shares of Optimer spiked higher following the report, closing up $1.85, or 14.44%, to $14.66. The report notes the company disclosed almost three months ago it was exploring its strategic options. Reference Link 15:55 EDT AZN Optimer gets first round bids from AstraZeneca, Cubist, Bloomberg says Subscribe for More Information May 10, 2013 11:48 EDT AZN Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.